A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

This study is testing a new immune cell therapy (called CTA101, a CAR-T cell treatment) for patients with relapsed or treatment-resistant blood cancers — specifically B-cell acute lymphoblastic leukemia (B-ALL) or aggressive B-cell lymphoma (like DLBCL) — that have not responded to standard treatments. **You may be eligible if...** - You have B-cell acute lymphoblastic leukemia (ALL) and are between 3 and 70 years old, with cancer that keeps coming back or doesn't respond to chemotherapy - OR you have aggressive B-cell lymphoma (DLBCL or related types) and are between 18 and 70 years old, with cancer that has relapsed or is refractory to second-line or later treatments - You have enough cancer cells detected in the bone marrow or lymph nodes **You may NOT be eligible if...** - You have had 2 or more prior CAR-T cell therapies - You have active, uncontrolled infection or HIV - You have serious organ failure (heart, lung, liver, or kidneys) - You have active autoimmune disease requiring systemic treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.